Form 4: AngioDynamics Director Eileen Auen Receives Annual Stock Compensation
Insider Transaction Report
AngioDynamics Inc. Director Eileen O'Shea Auen was granted 17,675 restricted stock units as annual compensation, which vested immediately upon grant.
Summary
- Eileen O'Shea Auen, a Director of AngioDynamics Inc. (ANGO), acquired 17,675 shares of common stock on July 16, 2025.
- The acquisition represents restricted stock units granted as regular annual compensation for her service as a director.
- The restricted stock units immediately vested at the time of grant.
- Following this transaction, Eileen O'Shea Auen beneficially owns a total of 104,718 shares of AngioDynamics common stock.
- A Substitute Power of Attorney, executed on January 20, 2025, appoints Lawrence T. Weiss as a substitute attorney-in-fact for Eileen O. Auen, replacing Stephen A. Trowbridge, for the purpose of filing SEC Forms 3, 4, and 5.
Sentiment
Score: 5
Explanation: The document is a routine SEC Form 4 filing detailing a director's compensation grant, which is a neutral event in terms of company performance or outlook.
Positives
- The restricted stock units granted to the director vested immediately, providing immediate ownership and liquidity.
- The grant of shares as compensation aligns the director's interests with those of the shareholders.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction; it is solely a report of an insider transaction.
Industry Context
This Form 4 filing details a routine compensation grant to a director, which is a common practice across industries to align management and board interests with shareholder value. It does not provide specific insights into broader industry trends or competitive landscape.
Comparison to Industry Standards
- The grant of restricted stock units as annual compensation for directors is a standard practice in publicly traded companies, including those in the medical technology sector like AngioDynamics.
- Immediate vesting of director compensation shares is also common, though some companies may implement deferred vesting schedules.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Substitution | Stephen A. Trowbridge, an attorney-in-fact for Eileen O. Auen, appointed Lawrence T. Weiss as a substitute attorney-in-fact to handle SEC Forms 3, 4, and 5 filings on behalf of Ms. Auen. This supersedes any prior substitute powers of attorney by Mr. Trowbridge for Ms. Auen. | 2025-01-20 | This change streamlines the process for SEC filings for the director, ensuring continuity and compliance with reporting obligations. It does not impact the director's role or responsibilities within the company. |
Related Party Transactions
- The acquisition of 17,675 shares by Eileen O'Shea Auen, a director, as annual compensation, constitutes a related party transaction between the company and a member of its board.
Stakeholder Impact
- Shareholders: Minor dilution due to the issuance of new shares for compensation, but the grant aligns the director's interests with shareholder value.
- Director (Eileen O'Shea Auen): Increased equity ownership in the company, providing a direct financial incentive tied to company performance.
Key Dates
| Date | Description |
|---|---|
| 2025-01-20 | Date of execution of the Substitute Power of Attorney appointing Lawrence T. Weiss. |
| 2025-07-16 | Date of the transaction where 17,675 restricted stock units were acquired and immediately vested. |
| 2025-07-18 | Date the Form 4 filing was signed by the attorney-in-fact. |
Keywords
AngioDynamics, ANGO, SEC Form 4, insider transaction, restricted stock units, director compensation, equity grant, corporate governance, stock ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.